Table 3.

Cumulative Incidence of Renal Outcomes in the Trials (Combined incidence in treatment and control arms)

	Kumamoto	UKPDS 33	UKPDS 34	VA Diabetes Feasibility Trial	ACCORD	ADVANCE	VADT
Median length of follow-up (yrs)	6	10	10.7	2	5	5	6
Microalbuminuria	15.6%	21.0%*	23%	44%	23.5%	24.7%	11.5%
Macroalbuminuria	3.9%	5.0%*	…	8.5%	4.6%	3.5%	4.0%
Doubling of Creatinine	…	1.0%*	…	…	7.4%	1.1%	8.8%
ESRD	…	0.6%†	0.5%	…	2.8%	0.5%	1.0%
Death from Renal Failure	…	0.3%†	0.4%	…	…	0.5%	…

^*At 9 years follow-up

^†At study end (median 11.1 years of follow-up)

…=Not Reported